A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, dose-escalation study of CUDC-101 in patients with advanced
and refractory solid tumors. CUDC-101 is a multi-targeted agent designed to inhibit epidermal
growth factor receptor (EGFR), human epidermal growth factor receptor Type 2(Her2) and
histone deacetylase (HDAC). The study is designed to establish the safety, including the
maximum tolerated dose, the pharmacokinetics, and the anti-tumor activity of CUDC-101.